Eudaimonia Advisors LLC Has $1.18 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Eudaimonia Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 2,031 shares of the company’s stock after buying an additional 100 shares during the quarter. Eudaimonia Advisors LLC’s holdings in Eli Lilly and Company were worth $1,184,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Vanguard Group Inc. raised its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Morgan Stanley raised its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after buying an additional 83,915 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Eli Lilly and Company by 3.6% during the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after buying an additional 355,317 shares in the last quarter. International Assets Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 61,268.8% during the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Eli Lilly and Company by 2.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock worth $2,382,339,000 after buying an additional 88,016 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY traded up $14.36 on Tuesday, hitting $745.69. 2,041,178 shares of the stock traded hands, compared to its average volume of 3,051,032. The business’s fifty day moving average is $763.83 and its two-hundred day moving average is $662.78. Eli Lilly and Company has a 12 month low of $370.68 and a 12 month high of $800.78. The firm has a market capitalization of $708.52 billion, a price-to-earnings ratio of 127.57, a PEG ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the company earned $2.09 earnings per share. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.